These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 26684030)
1. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030 [TBL] [Abstract][Full Text] [Related]
2. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501 [TBL] [Abstract][Full Text] [Related]
3. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis. Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681 [TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973 [TBL] [Abstract][Full Text] [Related]
5. Platelet-activating factor podoplanin: from discovery to drug development. Takemoto A; Miyata K; Fujita N Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748 [TBL] [Abstract][Full Text] [Related]
6. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756 [TBL] [Abstract][Full Text] [Related]
7. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Ogasawara S; Kaneko MK; Price JE; Kato Y Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544 [TBL] [Abstract][Full Text] [Related]
8. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683 [TBL] [Abstract][Full Text] [Related]
10. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey ( Ukaji T; Takemoto A; Katayama R; Takeuchi K; Fujita N Oncotarget; 2018 Sep; 9(70):33322-33336. PubMed ID: 30279963 [TBL] [Abstract][Full Text] [Related]
11. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532 [TBL] [Abstract][Full Text] [Related]
12. A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. Takemoto A; Okitaka M; Takagi S; Takami M; Sato S; Nishio M; Okumura S; Fujita N Sci Rep; 2017 Feb; 7():42186. PubMed ID: 28176852 [TBL] [Abstract][Full Text] [Related]
13. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201 [TBL] [Abstract][Full Text] [Related]
14. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Kunita A; Kashima TG; Morishita Y; Fukayama M; Kato Y; Tsuruo T; Fujita N Am J Pathol; 2007 Apr; 170(4):1337-47. PubMed ID: 17392172 [TBL] [Abstract][Full Text] [Related]
15. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Takagi S; Oh-hara T; Sato S; Gong B; Takami M; Fujita N Int J Cancer; 2014 Jun; 134(11):2605-14. PubMed ID: 24222607 [TBL] [Abstract][Full Text] [Related]
16. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352 [TBL] [Abstract][Full Text] [Related]
18. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Oki H; Ogasawara S; Kaneko MK; Takagi M; Yamauchi M; Kato Y Monoclon Antib Immunodiagn Immunother; 2015 Feb; 34(1):44-50. PubMed ID: 25723283 [TBL] [Abstract][Full Text] [Related]
19. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis. Sheng M; Sun R; Fu J; Lu G BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690 [TBL] [Abstract][Full Text] [Related]
20. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma. Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]